Get started
Live feed
PRReleasevia Quantisnow
ImmunityBio Inc. logo

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for IBRX

Across the 8 sessions after earlier IBRX headlines, the stock closed higher 6 times and lower 2 times, with a median move of 7.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

IBRX close-to-close change in the session after earlier headlines
SessionEarlier headlineIBRXSPY
Jan 15, 2026ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year+30.8%+0.3%
Jan 14, 2026Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancerand 1 other headline that session+7.1%-0.5%
Jan 13, 2026ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer+8.9%-0.2%
Jan 12, 2026NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security+11.2%+0.2%
Dec 29, 2025ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of "100 Most Influential People in Oncology in 2025"-4.7%-0.4%
Dec 16, 2025ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer-2.7%-0.3%
Quantisnow market dataNASDAQ
ImmunityBio Inc. logo
IBRX
ImmunityBio Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2015
Get push alerts for IBRX

Follow IBRX and get a push notification the moment its next story breaks.

Full IBRX profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IBRX (ImmunityBio Inc.) and more on Quantisnow.